Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 120 | $4.93 | $591.60 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 29 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,458 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,987 | $4.95 | $14,785.65 |
DisclosureSEC source: 0001209191-19-050361 · doc4.xml · nonDerivative · entry 4 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,170 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $4.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $4.81, inclusive. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 130 | $4.93 | $640.90 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 29 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,092 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 120 | $4.93 | $591.60 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 29 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,382 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 18, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.15 | $386.25 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 16 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,754 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 17, 2019 Filed Sep 20, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 711 | $4.91 | $3,491.01 |
DisclosureSEC source: 0001209191-19-050361 · doc4.xml · nonDerivative · entry 3 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,157 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. Read SEC document |
| September 16, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $4.97 | $298.20 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 28 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,338 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 16, 2019 Filed Sep 20, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 100 | $5.05 | $505.00 |
DisclosureSEC source: 0001209191-19-050361 · doc4.xml · nonDerivative · entry 2 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,868 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. Read SEC document |
| September 16, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $4.97 | $323.05 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 28 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,962 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 16, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $4.97 | $298.20 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 28 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,262 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 13, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 120 | $5.18 | $621.60 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 27 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,278 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 13, 2019 Filed Sep 20, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 3,117 | $5.11 | $15,927.87 |
DisclosureSEC source: 0001209191-19-050361 · doc4.xml · nonDerivative · entry 1 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,968 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $4.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.16 to $5.08, inclusive. Read SEC document |
| September 13, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 130 | $5.18 | $673.40 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 27 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,897 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 13, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 120 | $5.18 | $621.60 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 27 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,202 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 13, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.03 | $377.25 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 15 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,679 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 21:27 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,646 | $5.15 | $13,626.90 |
DisclosureSEC source: 0001209191-19-049507 · doc4.xml · nonDerivative · entry 5 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,085 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.40 to $4.90, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F6 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.13, inclusive. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 21:27 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,700 | $5.01 | $13,527.00 |
DisclosureSEC source: 0001209191-19-049507 · doc4.xml · nonDerivative · entry 4 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,731 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.40 to $4.90, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.06 to $4.96, inclusive. Read SEC document |
| September 11, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.02 | $301.20 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 26 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,158 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 11, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.02 | $326.30 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 26 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,767 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 11, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.02 | $301.20 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 26 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,082 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 10, 2019 Filed Sep 13, 2019 21:27 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,400 | $5.39 | $7,546.00 |
DisclosureSEC source: 0001209191-19-049507 · doc4.xml · nonDerivative · entry 3 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,431 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.40 to $4.90, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.40 to $5.34, inclusive. Read SEC document |
| September 10, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.38 | $322.80 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 25 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,098 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 10, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.38 | $349.70 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 25 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,702 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 10, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.38 | $322.80 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 25 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,022 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 10, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.19 | $389.25 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 14 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,604 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 09, 2019 Filed Sep 13, 2019 21:27 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,300 | $5.24 | $12,052.00 |
DisclosureSEC source: 0001209191-19-049507 · doc4.xml · nonDerivative · entry 2 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,831 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.40 to $4.90, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.39 to $5.11, inclusive. Read SEC document |
| September 09, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.19 | $311.40 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 24 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,038 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 09, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.19 | $337.35 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 24 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,637 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 09, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.19 | $311.40 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 24 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,962 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 06, 2019 Filed Sep 13, 2019 21:27 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 400 | $4.91 | $1,964.00 |
DisclosureSEC source: 0001209191-19-049507 · doc4.xml · nonDerivative · entry 1 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,131 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. Read SEC document |
| September 06, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 120 | $4.91 | $589.20 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 23 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,978 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 06, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 130 | $4.91 | $638.30 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 23 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,572 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 06, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 120 | $4.91 | $589.20 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 23 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,902 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 05, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.01 | $375.75 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 13 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,529 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 04, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $4.79 | $287.40 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 22 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,858 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 04, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $4.79 | $311.35 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 22 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,442 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 04, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $4.79 | $287.40 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 22 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,782 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 30, 2019 Filed Aug 30, 2019 21:18 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 900 | $5.11 | $4,599.00 |
DisclosureSEC source: 0001209191-19-047851 · doc4.xml · nonDerivative · entry 5 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,531 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.07, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.12 to $5.07, inclusive. Read SEC document |
| August 30, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.14 | $308.40 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 21 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,798 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 30, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.14 | $334.10 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 21 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,377 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 30, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.14 | $308.40 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 21 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,722 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 29, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 120 | $5.04 | $604.80 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 20 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,738 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 29, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 130 | $5.04 | $655.20 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 20 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,312 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 29, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 120 | $5.04 | $604.80 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 20 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,662 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 29, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $4.98 | $373.50 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 12 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,454 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 28, 2019 Filed Aug 30, 2019 21:18 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 200 | $5.02 | $1,004.00 |
DisclosureSEC source: 0001209191-19-047851 · doc4.xml · nonDerivative · entry 4 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,431 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. Read SEC document |
| August 27, 2019 Filed Aug 30, 2019 21:18 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 100 | $5.11 | $511.00 |
DisclosureSEC source: 0001209191-19-047851 · doc4.xml · nonDerivative · entry 3 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,631 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. Read SEC document |
| August 27, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 120 | $5.19 | $622.80 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 19 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,618 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 27, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 130 | $5.19 | $674.70 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 19 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,182 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 27, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 120 | $5.19 | $622.80 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 19 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,542 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.